DarioHealth Corp. (DRIO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
DarioHealth Corp. (DRIO) dropped -2.93% to $3.31, trading at 3% of its 52-week range ($3 – $14.77). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
DarioHealth is back in focus after an analyst fair value estimate shifted from US$15.25 to about US$12.33, a reduction of a little over 19% that resets expectations around the stock. Recent research blends optimism about
Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
BTIG analyst David Larsen initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $6.
DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that a leading regional gr
Contract extension follows benefits realized from Dario's cardiometabolic program and strong employee demand for perimenopause supportNearly 45% of Dario's current book of business is women over age 40 who could
Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DRIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DRIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, DarioHealth Corp. (DRIO) ranks #795 by composite RQD confidence (36/100, grade D-) and #794 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with DRIO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DRIO
ACTIVE
DarioHealth Corp. | D- | 36/100 | — | 56.6% | -35.0% | -2.93% | $32.4M | Benchmark Subject |
| BEAT Heartbeam Inc. | D | 50/100 | — | — | -35.0% | +1.34% | $30.4M | /beat-vs-drio → |
| NEPH Nephros Inc. | B | 73/100 | 29.8x | 61.9% | 18.9% | +3.16% | $35.5M | /neph-vs-drio → |
| CVRX CVRx Inc. | D- | 43/100 | — | 85.3% | -35.0% | +1.79% | $38.0M | /cvrx-vs-drio → |
| XTNT Xtant Medical Holdings Inc. | C+ | 69/100 | — | 62.9% | 12.8% | +1.54% | $40.7M | /xtnt-vs-drio → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), DarioHealth Corp. (DRIO) reported GAAP revenue of $22.4M (-17.3% vs. FY2024 revenue of $27.0M ) , GAAP net income of -$41.7M, operating cash flow of -$25.9M, and free cash flow of -$26.1M (+32.6% YoY). On the balance sheet, DRIO closed FY2025 with $110.1M in total assets against $30.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $22.4M | -$41.7M | -$25.9M | -$26.1M | $110.1M | $30.7M |
| FY2024 (FY) | 2024-12-31 | $27.0M | -$42.7M | -$38.6M | -$38.7M | $118.9M | $23.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$59.4M | -$30.4M | -$30.4M | — | — |
As of 2026-11-01, DarioHealth Corp. (NASDAQ: DRIO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.31 (-2.93% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DRIO ranks #795 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $30.4M) and NEPH (Nephros Inc.) posts a B grade (73/100 RQD, P/E 29.8x, ROIC 18.9%, cap $35.5M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).
Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DRIO last traded at $3.31 (-2.93% on volume of 59,443 shares), positioning the stock -44.65% below its 50-day simple moving average ($5.98) and -57.24% below its 200-day simple moving average ($7.74). Across its 52-week range of $3.00 to $14.77, DRIO sits at the 2.6% percentile with a 14-day RSI of 23.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).
Why DRIO Stock dropped -2.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.